Search Results - "Gharib, Elie G."

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents by Kandzari, David E., Koolen, Jacques J., Doros, Gheorghe, Massaro, Joseph J., Garcia-Garcia, Hector M., Bennett, Johan, Roguin, Ariel, Gharib, Elie G., Cutlip, Donald E., Waksman, Ron

“…Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture, and bioresorbable polymers. Whether these advancements…”
Get full text

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial by Kandzari, David E, Mauri, Laura, Koolen, Jacques J, Massaro, Joseph M, Doros, Gheorghe, Garcia-Garcia, Hector M, Bennett, Johan, Roguin, Ariel, Gharib, Elie G, Cutlip, Donald E, Waksman, Ron

“…The development of coronary drug-eluting stents has included use of new metal alloys, changes in stent architecture, and use of bioresorbable polymers. Whether…”
Get full text

Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial by Kandzari, David E, Koolen, Jacques J, Doros, Gheorghe, Garcia-Garcia, Hector M, Bennett, Johan, Roguin, Ariel, Gharib, Elie G, Cutlip, Donald E, Waksman, Ron

“…The aim of this study was to compare late-term clinical outcomes among patients treated with ultrathin-strut (60-μm) bioresorbable-polymer sirolimus-eluting…”
Get full text

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes by Kandzari, David E, Koolen, Jacques J, Doros, Gheorghe, Garcia-Garcia, Hector M, Bennett, Johan, Roguin, Ariel, Gharib, Elie G, Cutlip, Donald E, Waksman, Ron

“…BACKGROUNDRandomized trials have demonstrated the superiority of ultrathin strut drug-eluting stents compared with alternative stent designs. Whether these…”
Get full text

Advances in the management of hyperkalemia in chronic kidney disease by Cowan, Andrea C.J, Gharib, Elie G, Weir, Matthew A

“…PURPOSE OF REVIEWPatients with chronic kidney disease (CKD) have an increased risk of hyperkalemia that increases both short-term and long-term mortality…”
Get full text

Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients: BIOFLOW V Acute Coronary Syndromes Subgroup by Roguin, Ariel, Kandzari, David E, Marcusohn, Erez, Koolen, Jacques J, Doros, Gheorghe, Massaro, Joseph M, Garcia-Garcia, Hector M, Bennett, Johan, Gharib, Elie G, Cutlip, Donald E, Waksman, Ron

“…BACKGROUND:Presentation with acute coronary syndromes (ACS) constitutes a high-risk subset of patients with worse outcome after percutaneous coronary…”
Get full text

Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization by Kandzari, David E., Koolen, Jacques J., Doros, Gheorghe, Garcia-Garcia, Hector M., Bennett, Johan, Roguin, Ariel, Gharib, Elie G., Cutlip, Donald E., Waksman, Ron

“…The aim of this study was to compare late-term clinical outcomes among patients treated with ultrathin-strut (60-μm) bioresorbable-polymer sirolimus-eluting…”
Get full text

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents by Kandzari, David E., Koolen, Jacques J., Doros, Gheorghe, Garcia-Garcia, Hector M., Bennett, Johan, Roguin, Ariel, Gharib, Elie G., Cutlip, Donald E., Waksman, Ron

“…Randomized trials have demonstrated the superiority of ultrathin strut drug-eluting stents compared with alternative stent designs. Whether these differences…”
Get full text

CRT-600.03 Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization: Final Five-Year Outcomes From the Randomized BIOFLOW-V Trial by Kandzari, David E., Koolen, Jacques J., Doros, Gheorghe, Garcia-Garcia, Hector M., Bennett, Johan, Roguin, Ariel, Gharib, Elie G., Cutlip, Donald E., Waksman, Ron

Get full text

CRT-500.02 Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization: Three-Year Outcomes From the Randomized BIOFLOW V Trial by Kandzari, David E., Koolen, Jacques J., Doros, Gheorghe, Garcia-Garcia, Hector M., Bennett, Johan, Roguin, Ariel, Gharib, Elie G., Cutlip, Donald E., Waksman, Ron

Get full text

Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization: Final Five-Year Outcomes From the Randomized BIOFLOW-V Trial by Kandzari, David E., Koolen, Jacques J., Doros, Gheorghe, Garcia-Garcia, Hector M., Bennett, Johan, Roguin, Ariel, Gharib, Elie G., Cutlip, Donald E., Waksman, Ron

Get full text

Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients by Roguin, Ariel, Kandzari, David E, Marcusohn, Erez, Koolen, Jacques J, Doros, Gheorghe, Massaro, Joseph M, Garcia-Garcia, Hector M, Bennett, Johan, Gharib, Elie G, Cutlip, Donald E, Waksman, Ron

“…Presentation with acute coronary syndromes (ACS) constitutes a high-risk subset of patients with worse outcome after percutaneous coronary intervention. We…”
Get full text